Slowing Tecfidera Sales Increases Biogen's (BIIB) M&A Risk - Moody's

Moody's Investors Service commented that slowing sales of Tecfidera, the largest product of Biogen (NASDAQ: BIIB) increases the event risk of acquisitions. That said, there is currently no effect on Biogen's Baa1 senior unsecured rating or stable rating outlook based on strong financial flexibility.

You May Also Be Interested In

• Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
• UBS Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral
• Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong